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Evaluation of an Immunochromatographic Assay for Rapid Detection
of Penicillin-Binding Protein 2a in Human and Animal Staphylococcus
intermedius Group, Staphylococcus lugdunensis, and Staphylococcus
schleiferi Clinical Isolates
Emory University School of Medicine, Atlanta, Georgia, USAa; Washington University in St. Louis School of Medicine, St. Louis, Missouri, USAb; University of Iowa Hospitals
and Clinics, Iowa City, Iowa, USAc; College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USAd; Centers for Disease Control
and Prevention, Atlanta, Georgia, USAe; Children’s Healthcare of Atlanta, Atlanta, Georgia, USAf; Emory Antibiotic Resistance Center, Atlanta, Georgia, USAg; Weill Cornell
Medical College, New York, New York, USAh

The performance of a rapid penicillin-binding protein 2a (PBP2a) detection assay, the Alere PBP2a culture colony test, was evaluated for identification of PBP2a-mediated beta-lactam resistance in human and animal clinical isolates of Staphylococcus intermedius group, Staphylococcus lugdunensis, and Staphylococcus schleiferi. The assay was sensitive and specific, with all PBP2anegative and PBP2a-positive strains testing negative and positive, respectively.

T

he genus Staphylococcus is currently composed of 47 species
and 23 subspecies (1). Most members of the genus are resident
flora; however, certain species are endowed with pathogenic traits
and can cause serious disease (1). Clinically, Staphylococcus aureus
is the most significant species worldwide (2, 3), but non-S. aureus
species of medical and veterinary importance include members of
the Staphylococcus intermedius group (S. pseudintermedius, S. intermedius, and S. delphini), Staphylococcus lugdunensis, Staphylococcus schleiferi subsp. coagulans, and S. schleiferi subsp. schleiferi
(1, 4–6). These species cause a wide spectrum of diseases ranging
from skin and soft tissue infections and infective endocarditis to
foreign-body-related infections, and they pose a significant threat
to human and animal health (1, 4–6). For instance, S. pseudintermedius accounts for the majority of Staphylococcus species isolated
from canine clinical specimens and is an emerging agent of human
infection (7, 8), while S. lugdunensis has an S. aureus-like proclivity for aggressive disease, notably infectious endocarditis, in humans and animals (9, 10).
Antibiotic treatment of staphylococci can be impeded by their
ability to acquire resistance to multiple classes of antibiotics, especially beta-lactams (3). In staphylococci, beta-lactam resistance
is typically conferred by the acquisition of an alternative penicillin-binding protein, penicillin-binding protein 2a (PBP2a or
PBP2=), encoded by mecA, which catalyzes the synthesis of the
bacterial cell wall in the presence of otherwise inhibitory concentrations of beta-lactam (3, 11). Although methicillin is no longer
used clinically, staphylococcal isolates that contain mecA, and thus
PBP2a, are called methicillin resistant, while isolates lacking mecA
are designated methicillin susceptible (3). Presently, methicillinresistant staphylococcal isolates are resistant to all beta-lactams,
with the exception of the latest cephalosporin variants ceftobiprole and ceftaroline (12), and are of major medical and veterinary concern.
The prevalence of mecA-mediated beta-lactam resistance in S.
lugdunensis is low (13); however, the number of methicillin-resistant S. intermedius group isolates is increasing at an alarming rate
(14). Furthermore, these methicillin-resistant isolates exhibit a
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multidrug resistance phenotype that likely arose from indiscriminate use of antibiotics in the animal population (14, 15).
Therefore, by limiting treatment options and threatening the
conservation of antibiotic efficacy in animals, multidrug-resistant S. intermedius group isolates are a threat to animal health.
Similarly, they are a danger to human wellbeing through transmission to humans and present a reservoir of antibiotic resistance.
Further complicating the issue is the poor sensitivity of some phenotypic assays, in particular cefoxitin disk diffusion, to detect
mecA-mediated resistance in S. intermedius group and S. schleiferi
isolates (16). Thus, rapid, accurate, and inexpensive methods to
differentiate methicillin-susceptible and methicillin-resistant S.
intermedius group, S. lugdunensis, and S. schleiferi isolates will
greatly facilitate the management of infections due to these species
in human and animal populations.
Herein, we assess the diagnostic performance of a rapid immunochromatographic assay, the Alere PBP2a culture colony test, to
detect PBP2a in human and animal S. intermedius group, S. lugdunensis, and S. schleiferi clinical isolates grown in culture. The
assay, indicated for the detection of PBP2a in S. aureus (17), is
facile and differentiates methicillin-susceptible and methicillinresistant isolates in approximately 5 min, which is considerably
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TABLE 1 Staphylococcus intermedius group, S. lugdunensis, and S. schleiferi clinical isolates of human and animal origin included in the study

Geographic
origin of
isolates (no.)
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faster than conventional phenotypic-based methods (18), resulting in the opportunity for rapid administration of appropriate
antistaphylococcal antibiotics (19).
The collection of strains analyzed in this study is tabulated in
Table 1. It was composed of 127 clinical isolates (101 mecA negative and 26 mecA positive) obtained from humans (104 isolates; 95
mecA negative and 9 mecA positive) and animals (23 isolates; 6
mecA negative and 17 mecA positive) and included 37 S. intermedius group, 67 S. lugdunensis, 12 S. schleiferi subsp. coagulans, and
11 S. schleiferi subsp. schleiferi isolates. Organisms were obtained
from four geographically distinct sites in the United States, including 12 from Georgia, 24 from Iowa, 36 from Missouri, and 20 from
Texas. In addition, 35 isolates sent to the Centers for Disease Control and Prevention for reference identification from state health
departments across the United States were included. A single isolate was obtained per subject.
The identity of each strain was confirmed to the species level
using matrix-assisted laser desorption ionization–time of flight
mass spectrometry (20). Mass spectra were obtained with a Microflex LT mass spectrometer (Bruker Daltonics, Billerica, MA),
and the resultant spectra were queried against the Biotyper database (5,627 entries; Bruker Daltonics). Isolates identified as S. intermedius or S. pseudintermedius were reported as S. intermedius
group (no S. delphini isolates were included in the collection). To
confirm S. schleiferi to the subspecies-level, urea hydrolysis and
free (tube) coagulase (S. schleiferi subsp. coagulans, positive; S.
schleiferi subsp. schleiferi, negative) were assayed using urea agar
(Thermo Fisher Scientific, Waltham, MA) and rabbit coagulase
plasma (Thermo Fisher Scientific).
Prior to testing, organisms were passaged twice on tryptic soy
agar with 5% sheep blood (TSAB) (Thermo Fisher Scientific) and
incubated at 35°C in 5% to 10% carbon dioxide. After the first
passage, cultures were incubated between 18 and 24 h before subculture, while after the second passage, cultures were incubated
between 22 and 24 h before analysis. Testing was performed per
the manufacturer’s instructions (17) and without knowledge of
the mecA PCR result. On all days of testing, both a negative control, methicillin-susceptible S. aureus (S. aureus ATCC 25923),
and a positive control, methicillin-resistant S. aureus (S. aureus
ATCC 43300), were analyzed in conjunction with test isolates.
The reference method for detecting mecA (PBP2a)-mediated
beta-lactam resistance was mecA PCR. Fragments of the mecA
gene and an internal control were detected using a multiplex PCR
assay (21). A bacterial extract containing genomic DNA was prepared by resuspending colonies in 50 l of nuclease-free water
(BioExpress, Kaysville, UT) and by heating at 100°C for 10 min.
Cellular debris was removed by centrifugation for 5 min at 21,130 ⫻
g. Each PCR mixture contained 2 l of the bacterial extract (between
50 and 200 ng of DNA), primers at a final concentration of 0.5 M,
and 10 l of 2⫻ AmpliTaq Gold Fast PCR master mix (Applied
Biosystems, Foster City, CA) in a final volume of 20 l. The mixture was cycled as follows: 10 min at 95°C, 35 cycles of 3 s at 96°C,
3 s at 52°C, and 5 s at 68°C, followed by 10 s at 72°C. The resultant
PCR products were analyzed using agarose gel electrophoresis.
Again, negative (S. aureus ATCC 25923) and positive (S. aureus
ATCC 43300) controls were analyzed in conjunction with test
isolates on all days of analysis. Immunochromatographic assay
results were defined as true negative (TN) (immunochromatographic assay and mecA PCR negative), true positive (TP) (immunochromatographic assay and mecA PCR positive), false negative

S.
schleiferi
subsp.
schleiferi
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TABLE 2 Diagnostic performance of the Alere PBP2a culture colony
test for detecting PBP2a-mediated beta-lactam resistance in S.
intermedius group, S. lugdunensis, and S. schleiferi clinical isolates of
human and animal origin
Sensitivity (%)

Specificity (%)

Human

Animal

Human

Animal

S. intermedius group
S. lugdunensis
S. schleiferi subsp. coagulans
S. schleiferi subsp. schleiferi

100
100
100
N/Ac

100
N/Aa,b
100
N/Ab,c

100
100
100
100

100
N/Ab
100
N/Ab

a

N/A, not available.
No animal isolates available for analysis.
c
No mecA-positive isolates.
b

(FN) (immunochromatographic assay negative and mecA PCR
positive), or false positive (FP) (immunochromatographic assay
positive and mecA PCR negative). Diagnostic performance was
assessed using the equations for sensitivity, TP/(TP ⫹ FN), and
specificity, TN/(TN ⫹ FP).
Of the 127 clinical isolates analyzed, 104 and 23 were obtained
from human and animal sources, respectively, and 101 were mecA
negative and 26 were mecA positive (Table 1). Compared to mecA
PCR, the immunochromatographic assay was highly sensitive and
specific (Table 2). All 101 mecA-negative strains tested negative
and all 26 mecA-positive strains tested positive, irrespective of
species or geographic and subject origin. Compare this to S. aureus
(the intended test organism); an investigation of 661 S. aureus
isolates revealed PBP2a culture colony test assay sensitivity and
specificity values of 98.4% and 100%, respectively (19). Therefore,
it is clear that PBP2a-negative and PBP2a-positive S. intermedius
group, S. lugdunensis, and S. schleiferi isolates are readily differentiated using the Alere PBP2a culture colony test, and the diagnostic performance is equivalent to that observed for S. aureus. Nevertheless, a limitation of our study was the lack of mecA-positive S.
schleiferi subsp. schleiferi isolates (which we did not have in our
possession); as such, it was not possible to determine the sensitivity of the assay for the detection of PBP2a in this subspecies.
To ensure preanalytic consistency during our evaluation, all
127 isolates were analyzed after growth on TSAB for 22 to 24 h. To
understand if non-S. aureus isolates could be tested under clinically relevant conditions (i.e., growth on TSAB between 18 to 24
h), we assayed six isolates (three mecA negative and three mecA
positive) each of S. intermedius group, S. lugdunensis, and S. schleiferi subsp. coagulans at 18 and 24 h postculture. Regardless of the
species and incubation time, all mecA-negative isolates were
PBP2a negative and all mecA-positive isolates were PBP2a positive
at 18 and 24 h postculture, respectively. These data revealed that
beta-lactam susceptibility information for non-S. aureus staphylococci isolates can be generated within a time frame equivalent to
that of nucleic-acid-based tests and considerably faster than that
of conventional phenotypic methods.
In summary, we assessed the diagnostic performance of an
immunochromatographic assay for the rapid detection of PBP2a
in human and animal S. intermedius group, S. lugdunensis, and S.
schleiferi clinical isolates. To the best of our knowledge, this is the
first study demonstrating the role of this assay for detecting PBP2a
in clinical non-S. aureus human and animal isolates. The assay
exhibited excellent diagnostic characteristics (Table 2) and was
unaffected by species identity or subject and geographic source.
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Organism

Recently, a new version of the Alere PBP2a assay, the PBP2a SA
culture colony test (22), was released. The diagnostic performances of the PBP2a culture colony test and the PBP2a SA culture
colony test for S. aureus grown on TSAB (the intended test organism for the two systems and the same medium employed in this
study) are equivalent; PBP2a culture colony test sensitivity and
specificity was ⬎98% and PBP2a SA culture colony test sensitivity
and specificity was ⬎99%. Consequently, the PBP2a SA culture
colony test should accurately differentiate PBP2a-negative and
PBP2a-positive S. intermedius group, S. lugdunensis, and S. schleiferi isolates. Therefore, we believe the Alere PBP2a culture colony
test (and the PBP2a SA culture colony test) will benefit medical
and veterinary clinical microbiologists and infectious disease specialists by affording rapid, accurate, and inexpensive detection of
PBP2a in S. intermedius group, S. lugdunensis, and S. schleiferi
isolates.
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